OHSU

IRB #

IRB00009553

Title

A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to compare the effects, good and/or bad, of cabozantinib (the study drug) with everolimus on participants and their metastatic renal cell carcinoma to find out which is better.

Medical Condition(s)

Locally advanced or metastatic renal cell carcinoma (mRCC).

Eligibility Criteria

Age ≥ 18, unresectable locally advanced or mRCC with one prior systemic treatment

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

As long as participants are seeing clinical benefit

Minors Included

No

Contact

Deidre Nauman
naumand@ohsu.edu
503-494-3078

Sponsor

Exelixis, Inc.

Recruitment End

12/31/2014

Compensation Provided

No


Go Back